Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone: A Retrospective Study on Behalf of the CTIWP

Études rétrospectives

Leucémie Aiguë Lymphoblastique (LAL)

Leucémie Myéloïde Aiguë (LMA)

Chronic Lymphocytic Leukaemia (CLL)

Leucémie Lymphoïde Chronique (LLC)

Chronic Lymphocytic Leukaemia (CLL)

Syndrome Myélodysplasique (MDS) ou MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Allogénique - Haplo-identique

Investigateur principal

Impact of body mass index on outcome of CART cell therapy

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Christian Schultze-Florey

Efficacy and outcomes of allogeneic hematopoietic stem cell boost in adult patients with poor graft function

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Tatiana Rudakova

Outcomes of Allogeneic Hematopoietic Cell Transplantation from ≤8/10-HLA matched unrelated donor

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

GVHD Prophylaxis with ATG or PTCy after alloSCT from unrelated donors

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

ATG in the MSD setting - a real-world evidence study based on the EBMT Registry

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Agnieszka Piekarska

Survey on the use of SGLT2 inhibitors in cell therapy including autologous and allogeneic hematopoietic stem cell transplantation and CART cell therapy

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Christian Schultze-Florey

How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Potential factors influencing CAR-T cell manufacturing in terms of production failures and out of specification (OOS) products on behalf of EBMT - CTIWP

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Post-transplant cyclophosphamide as GvHD prophylaxis in patients with aplastic anemia with different donors: a comparative study of the SAAWP EBMT

Études rétrospectives

Aplasie Médullaire

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Investigateur principal

Defining protective immune cell subsets and subpopulations thresholds following allogeneic hematopoietic stem cell transplantation

Études rétrospectives

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Marina Cavazzana

Setting the stage for newborn screening and gene therapy: a disease-specific retrospective survey of FHL2 and 3

Études rétrospectives

Troubles héréditaires

Inborn Errors Working Party (IEWP)

Type de traitement

Investigateur principal

Stephan Ehl, Despina Moshous, Claire Booth, Sujal Ghosh